ABVC BioPharma, Inc.
ABVC
$1.23
-$0.08-6.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 798.00K | 391.30K | 508.40K | 509.60K |
| Total Other Revenue | -- | -11.60K | -2.30K | -2.30K | -2.30K |
| Total Revenue | 0.00 | 798.00K | 391.30K | 508.40K | 509.60K |
| Cost of Revenue | -- | 0.00 | 300.00 | 500.00 | 800.00 |
| Gross Profit | 0.00 | 798.00K | 391.00K | 508.00K | 508.90K |
| SG&A Expenses | 7.03M | 5.53M | 4.25M | 2.93M | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.70K | 43.30K | 52.60K | 52.60K | 52.60K |
| Total Operating Expenses | 7.15M | 5.70M | 4.44M | 3.12M | 5.27M |
| Operating Income | -7.15M | -4.90M | -4.05M | -2.61M | -4.76M |
| Income Before Tax | -8.35M | -5.34M | -4.54M | -3.39M | -5.37M |
| Income Tax Expenses | 24.10K | 24.10K | 24.00K | -110.50K | -110.50K |
| Earnings from Continuing Operations | -8.38 | -5.36 | -4.56 | -3.28 | -5.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 468.40K | 283.90K | 335.60K | 364.90K | 356.30K |
| Net Income | -7.91M | -5.08M | -4.23M | -2.91M | -4.90M |
| EBIT | -7.15M | -4.90M | -4.05M | -2.61M | -4.76M |
| EBITDA | -7.12M | -4.87M | -4.02M | -2.57M | -4.73M |
| EPS Basic | -0.38 | -0.30 | -0.27 | -0.23 | -0.46 |
| Normalized Basic EPS | -0.20 | -0.17 | -0.16 | -0.13 | -0.28 |
| EPS Diluted | -0.39 | -0.30 | -0.28 | -0.23 | -0.46 |
| Normalized Diluted EPS | -0.20 | -0.17 | -0.16 | -0.13 | -0.28 |
| Average Basic Shares Outstanding | 80.34M | 68.81M | 57.96M | 51.90M | 46.67M |
| Average Diluted Shares Outstanding | 80.34M | 68.81M | 57.96M | 51.90M | 46.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |